Imagine a heart that can't pump blood well enough, causing fluid to build up in the lungs. Instead of operating on the heart itself, this device acts like a smart valve placed in the lung arteries to balance the pressure. If the doctor needs to change the treatment, they can simply 'undo' the device using a balloon, making it much safer than permanent heart surgery.
Middle- and late-stage heart failure patients are undertreated because they often don't qualify for risky heart surgery or transplants. This leads to frequent hospitalizations and massive healthcare costs.
A transcatheter-delivered implant placed in the pulmonary arteries that is 100% reversible via a ballooning procedure.
If you are a manufacturer dealing with the high risk of permanent heart implants — this project developed a stent-within-a-stent design that is 100% reversible. This reduces physician risk and increases patient confidence in adopting the therapy.
If you are a hospital network dealing with the fact that 4% of all EU hospitalisations are due to heart failure — this project developed a minimally invasive implant that reduces hospitalisations and ICU congestion.
If you are an insurer dealing with heart failure costs that surmount to 1-2% of total healthcare costs in Europe — this project developed a treatment to prevent disease escalation and diminish long-term drug intake.
The project expects to generate €15M in revenues in 2025 and €60M in 2026. Specific unit pricing is not provided in the available data.
The project focuses on finalizing clinical development and introducing the device into clinical routines in Europe, including the creation of over 95 jobs in strategic European locations.
Based on available project data, the device utilizes a proprietary stent-within-a-stent design and a transcatheter delivery system, though specific patent numbers are not listed.
The company expects to launch ContraBand in 2024.
The device is designed for full clinical flexibility, meaning it is compatible with current pharmacotherapies and other existing heart failure devices.
The project is led by a single SME, Restore Medical Ltd from Israel. This lean structure indicates a high level of control over the IP and a direct path to commercialization, as there are no university or research partners slowing down the transition from clinical development to market launch.
Contact Restore Medical Ltd in Israel regarding the ContraBand clinical rollout.
Contact us to explore licensing opportunities for the proprietary stent-within-a-stent technology.
